Put companies on watchlist
Novo Nordisk A/S
ISIN: US6701002056
WKN: 866931
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Novo Nordisk A/S · ISIN: US6701002056 · PR Newswire (ID: 20250807DC43685)
07 August 2025 10:00PM

NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit


NEW YORK, Aug. 7, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE: NVO) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Novo Nordisk securities between May 7, 2025 and July 28, 2025, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/NVO.

Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Novo Nordisk's representations regarding its growth potential were overstated and failed to account for the impact of the personalization exception to the compounded GLP-1 exclusion; (2) Defendants misrepresented the likelihood that patients using compounded GLP-1s would transition to Novo Nordisk's branded alternatives; and (3) Novo Nordisk significantly overstated both the size of the GLP-1 market and its ability to penetrate that market to sustain growth.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/NVO. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Novo Nordisk you have until September 30, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller

332-239-2660 | info@bgandg.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nvo-investor-alert-bronstein-gewirtz--grossman-llc-announces-that-novo-nordisk-as-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302521639.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

Visual performance / price development - Novo Nordisk A/S
Smart analysis and research tools can be found here.
MIC: XNYS
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2025
PR Newswire
Contact:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942